Table 1 Baseline characteristics of the rectal cancer patients before and after propensity score matching
| Â | Baseline | After propensity score matching | ||||
|---|---|---|---|---|---|---|
|  | Triweekly XELOX n = 277 | Capecitabine n = 533 | SMD | TriweeklyXELOX n = 191 | Capecitabine n = 319 | SMD |
Age (years) median (range) | 55 (24–79) | 58 (24–84) | − 0.259 | 56 (24–79) | 56 (24–84) | 0.006 |
Gender | ||||||
 Male | 184 (66.4%) | 346 (64.9%) |  | 124 (64.9%) | 201 (63.0%) |  |
 Female | 93 (33.6%) | 187 (35.1%) | 0.032 | 67 (35.1%) | 118 (37.0%) | 0.040 |
Treatment period | ||||||
 2007–2011 | 108 (39.0%) | 2 (0.4%) |  | 52 (27.2%) | 2 (0.6%) |  |
 2012–2017 | 169 (61.0%) | 531 (99.6%) | −0.792 | 139 (72.8%) | 317 (99.4%) | −0.598 |
Clinical stage | ||||||
 II | 29 (10.5%) | 34 (6.4%) |  | 15 (7.9%) | 26 (8.2%) |  |
 III | 248 (89.5%) | 499 (93.6%) | −0.133 | 176 (92.1%) | 293 (91.8%) | 0.011 |
cT stage | ||||||
 cT2 | 25 (9.0%) | 10 (1.9%) |  | 8 (4.2%) | 6 (1.9%) |  |
 cT3 | 102 (36.8%) | 222 (41.7%) |  | 73 (38.2%) | 136 (42.6%) |  |
 cT4 | 150 (54.2%) | 301 (56.5%) | −0.145 | 110 (57.6%) | 177 (55.5%) | −0.004 |
cN stage | ||||||
 cN- | 29 (10.5%) | 34 (6.4%) |  | 15 (7.9%) | 26 (8.2%) |  |
 cN+ | 248 (89.5%) | 499 (93.6%) | −0.134 | 176 (92.1%) | 293 (91.8%) | 0.011 |
Type of Radiation | ||||||
 3D-CRT | 134 (48.4%) | 88 (16.5%) |  | 50 (26.2%) | 77 (24.1%) |  |
 IMRT | 143 (51.6%) | 445 (83.5%) | −0.638 | 141 (73.8%) | 242 (75.9%) | −0.046 |
RT dose | ||||||
  < 45 Gy | 1 (0.4%) | 0 (0.0%) |  | 1 (0.5%) | 0 (0.0%) |  |
 45Gy–50Gy | 22 (7.9%) | 8 (1.5%) |  | 10 (5.2%) | 4 (1.3%) |  |
 50Gy/50.4 Gy | 254 (91.7%) | 525 (98.5%) | −0.370 | 180 (94.2%) | 315 (98.7%) | −0.305 |
Interval from RT to surgery (weeks), median (range) | 8 (4–20) | 9 (4.3–19.9) | −0.543 | 8.6 (3.9–20) | 9 (4.3–19.9) | −0.107 |
Type of Surgery | ||||||
 Abdominoperineal resection | 29 (10.5%) | 58 (10.9%) |  | 21 (11.0%) | 35 (11.0%) |  |
 Anterior resection | 240 (86.6%) | 468 (87.8%) |  | 165 (86.4%) | 280 (87.8%) |  |
 Other | 8 (2.9%) | 7 (1.3%) | 0.056 | 5 (2.6%) | 4 (1.3%) | 0.037 |
Adjuvant chemotherapy | ||||||
 Yes | 226 (81.6%) | 404 (75.8%) |  | 149 (78.0%) | 243 (76.2%) |  |
 No | 51 (18.4%) | 129 (24.2%) | 0.149 | 42 (22.0%) | 76 (23.8%) | 0.044 |